Fitaro 1.7 mg/0.75 ml (SC Injection)

1.7 mg pre-filled syringe: ৳ 1,200.00

Medicine Details

Category Details
Generic Semaglutide
Company Incepta pharmaceuticals ltd
Also available as
Orsema 05 mg injection Orsema 025 mg injection Fitaro 1 mg injection Fitaro 24 mg injection Fitaro 025 mg injection Fitaro 05 mg injection

Indications

  • Adjunct to diet and exercise for glycemic control in adults with type 2 diabetes mellitus
  • Reduction of risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease
  • Adjunct to reduced calorie diet for chronic weight management in adult patients with specific BMI and comorbid conditions

Pharmacology

  • GLP-1 analogue with 94% sequence similarity to human GLP-1
  • Reduces blood glucose in a glucose-dependent manner
  • Stimulates insulin secretion and lowers glucagon secretion
  • Minor delay in gastric emptying
  • Reduces body weight and body fat mass by reducing appetite

Dosage & Administration

  • Can be taken as a tablet or injection
  • Initial starter dose of 3mg once daily for 30 days
  • Maintenance dose of 7mg once daily and can be increased to 14mg once daily if needed
  • Subcutaneous injection of 0.25mg weekly, increasing to 1mg weekly if needed
  • Can be administered at any time of the day with or without meals

Interaction

  • Delays gastric emptying
  • Potential to impact the rate of absorption of concomitantly administered oral medicinal products

Contraindications

  • Hypersensitivity to the active substance or excipients

Side Effects

  • Hypoglycemia, especially when used with insulin or sulfonylurea
  • Frequent gastrointestinal disorders, nausea, diarrhea, vomiting, abdominal pain, and constipation
  • Mild or moderate allergic reactions, injection site reaction, lipodystrophy, pruritus, and rash

Pregnancy & Lactation

  • Should not be used during pregnancy
  • Discontinuation at least 2 months before a planned pregnancy
  • Not recommended during breastfeeding

Precautions & Warnings

  • Not for use in type 1 diabetes mellitus or diabetic ketoacidosis
  • Prompt discontinuation if pancreatitis is suspected
  • Monitoring for patients with diabetic retinopathy

Use in Special Populations

  • Safety and efficacy in children and adolescents below 18 years not established
  • No dose adjustment based on age
  • No dose adjustment required for patients with mild, moderate, or severe renal impairment
  • Not recommended for use in patients with end-stage renal disease
  • No dose adjustment required for patients with hepatic impairment

Overdose Effects

  • Reported overdose up to 4mg in a single dose and up to 4mg in a week
  • Most commonly reported adverse reaction is nausea
  • No specific antidote for overdose
  • Dose adjustment when added to existing metformin and/or thiazolidinedione therapy
  • Missed dose instructions

Therapeutic Class

  • GLP-1 receptor agonists

Storage Conditions

  • Store at 2°C to 8°C (in a refrigerator)
  • Do not freeze
  • Keep out of reach of children

Related Brands